Full Length Research Paper
References
|
Adham M, Greijer AE, Verkuijlen SAWM, Juwana H, Fleig S, Rachmadi L, Malik O, Kurniawan AN, Roezin A, Gondhowiardjo S, Atmakusumah D, Stevens SJC, Herman B, Tan IB, Middeldorp JM (2013). Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment. Clin. Cancer Res. 19(8):2175-2186. Crossref |
||||
|
Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM (2012). Nasopharyngeal cancer in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin. J. Cancer 31(4):185-196. Crossref |
||||
|
Ai P, Wang T, Zhang H, Wang Y, Song C, Zhang L, Li Z, Hu H (2013). Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol. 49(4):326-331. Crossref |
||||
|
Chang C, Middeldorp J, Yu KJ, Juwana H, Hsu WL, Lou PJ, Wang CP, Chen JY, Liu MY, Pfeiffer RM, Chen CJ, Hildesheim A (2013). Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr antibodies associated with nasopharyngeal carcinoma. J. Med. Virol. 85(3):524-529. Crossref |
||||
|
Chang ET, Adami HO (2006). The Enigmatic Epidemiology of Nasopharyngeal Cancer. Cancer Epidemiol. Biomarkers Prev. 15:1765-1777. Crossref |
||||
|
Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS (2001). Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345:1877-1882. Crossref |
||||
|
Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM (2004). Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J. Infect. Dis. 190(1):53-62. Pubmed |
||||
|
Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM (2006). Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J. Clin. Microbiol. 44(4):1459-1467. Crossref |
||||
|
Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley ML (2004). Laboratory Markers of Tumor Burden in Nasopharyngeal Carcinoma: A comparison of Viral Load and Serologic test for Epstein-Barr Virus. Int. J. Cancer 112(6):1036-1041. Crossref |
||||
|
Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, Barbosa MM, Gonçalves FB Jr (2003). Prognostic factors and outcome for nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg.129(7):794-799. Crossref |
||||
|
Gu AD, Lu XL, Xie YB, Chen LZ, Feng QS, Kang T, Jia WH, Zeng YX (2009). Clinical values of multiple Epstein-Barr virus (EBV) serolo-gical biomarkers detected by xMAP technology. J. Transl. Med. 7:73. Crossref |
||||
|
Gulley ML (2001). Molecular diagnosis of Epstein-Barr virus-related diseases. J. Mol. Diagn. 3(1):1-10. Pubmed |
||||
|
Hassen E, Farhat K, Gabbouj S, Bouaouina N, Abdelaziz H, Chouchane L (2011). Epstein-Barr virus DNA quantification and follow up in Tunisian nasopharyngeal cancer patients. Biomarker. 16(3):274-280. Crossref |
||||
|
Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P, de Schryver A, de-Thé G, Diehl V, Klein G (1970). Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms and control groups. J. Natl. Cancer Inst. 44(1):225-231. Pubmed |
||||
|
Henle G, Henle W (1976). Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of Nasopharyngeal carcinoma. Int. J. Cancer 17(1):1-7. Crossref |
||||
|
Hess RD (2004). Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J. Clin. Microbiol. 4(8):3381-3387. Crossref |
||||
|
Ho HC, Ng MH, Kwan HC, Chau JC (1976). Epstein-Barr virus-specific IgA and IgG serum antibodies nasopharyngeal carcinoma. Br. J. Cancer. 34:655-660. Crossref |
||||
|
Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT, Sham JS, Ng MH (2007). Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 96(4):623-630. Crossref |
||||
|
Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM (2005). Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J. Med. Virol. 75(4):593-602. Crossref |
||||
|
Ling W, Cao SM, Huang QH, Li YH, Deng MQ (2009). Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong. Ai Zheng 28(1):57-59. Pubmed |
||||
|
Liu MY, Huang YT, Sheen TS, Chen JY, Tsai CH (2004). Immune responses to Epstein–Barr virus lytic proteins in patients with nasopharyngeal carcinoma. J. Med. Virol. 73(4):574-582. Crossref |
||||
|
Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M (2012). Establishment of VCA and EBNA 1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for naopharyngeal carcinoma: a two stage design with a preliminary performance study and a mass screening in southern China. Int. J. Cancer 131(2):406-416. Crossref |
||||
|
Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ (2000). Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 60(24):6878-6881. Pubmed |
||||
|
Middeldorp JM, Brink AATP, van den Brule A, Meijer CJLM (2003). Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit. Rev. Oncol. Hematol. 45(1):1-36. Crossref |
||||
|
Neel HB, Taylor WF (1990). Epstein-Barr virus-related antibody. Change in titers after therapy for nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 116(11):1287-1290. Crossref |
||||
|
Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N (1995). Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333(11):693-698. Crossref |
||||
| Raab-Traub N (2000). Epstein-Barr virus and nasopharyngeal carcinoma, In: J. A. Goedert (ed.), Infectious causes of cancer: targets for intervention. Humana Press,Totowa. N. J. pp. 93-111. | ||||
|
Sam CK, Abu-Samah AJ, Prasad U (1994). IgA/VCA as follow-up marker in the monitoring of nasopharyngeal carcinoma. Eur. J. Surg. Oncol. 20(5):561-564. |
||||
|
Sham ST, Choy D (1990). Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br. J. Radiol. 63(745):51-58. Crossref |
||||
|
Yu MC, Yuan JM (2002). Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 12(6):421-429. |
||||
|
Tao Q, Young LS, Woodman CB, Murray PG (2006). Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 11:2672-2713. Crossref |
||||
|
Tsuchiya S (2002). Diagnosis of Epstein-Barr virus-associated diseases. Crit. Rev. Oncol. Hematol. 44(3):227-238. Crossref |
||||
|
Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, Jin YT, Lin JC (2007). Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 67(1):130-137. Crossref |
||||
|
de-Vathaire F, Sancho-Garnier H, de-Thé H, Pieddeloup C, Schwaab G, Ho JH, Ellouz R, Micheau C, Cammoun M, Cachin Y, de-Thé G (1988). Prognostic value of EBV markers in the clinical management nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int. J. Cancer 42(2):176-181. Crossref |
||||
|
Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH (2003). Quantitative Epstein-Barr Virus (EBV) serology in lung transplant recipients with primary EBV infections and/or post-transplant lympho proliferative disease. J. Med. Virol. 69(2):258-266. Crossref |
||||
|
Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, Shih YT, Chen CC, Lin PJ, Liu YC, Lin JC (2013). Longterm survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA level. Cancer 119(5):963-970. Crossref |
||||
|
Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, Stoker S, Kurnianda J, Karakullukcu B, Taroeno-Hariadi KW, Hamming-Vrieze O, Middeldorp JM, Hariwiyanto B, Haryana SM, Tan IB (2013). Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. Plos one 8(5):e63706. |
||||
| Wolf H, zur Hausen H, Becker Y (1973). Epstein-Barr viral genomes in epithelial nasopharyngeal carcinoma cells. Nature. 244:245-257. | ||||
|
Wu Z, Zeng RF, Su Y, Gu MF, Huang SM (2013). Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. Head Neck 35(5):689-694. Crossref |
||||
|
Yeung WM, Zong YS, Chiu CT, Chan KH, Sham JS, Choy DT, Ng MH (1993). Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int. J. Cancer 53(5):746-750. Crossref |
||||
|
Yip TTC, Ngan RKC, Lau WH, Poon YF, Joab I, Cochet C, Cheng AK (1994). A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74(9):2414-2424. Pubmed |
||||
|
Yip TTC, Ngan RKC, Fong AHW, Law SCK (2014). Application of circulating plasma/serum EBV DNA in clinical management of nasopahryngeal carcinoma. Oral Oncol. (In Press) Crossref |
||||
|
Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR (1982). Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, China. Int. J. Cancer 29(2):139-141. Crossref |
||||
|
Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, Zhu JS, Pan WJ, Liu YX, Wei ZN, Chen JY, Mo YK, Li EJ, Tan BF (1983). Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 20(4):190-194. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
